More Business Wire
View Older Stories View Newer Stories-
KKR Appoints Brian J. Lee to Board
-
Supreme to Bring Back Typhoo’s Iconic Gnu for National Advertising Campaign
-
Bleeding gums? Don't ignore the warning signs – the first stage of gum disease can be reversed
-
Maven Expands From Meeting Intelligence to Matter Intelligence
-
Seagate Simplifies High-Capacity Storage Scaling for AI and Cloud Infrastructure
-
Ridge Security Is the Only Vendor Listed Across Four Categories in Three Gartner Cybersecurity Reports
-
Havas Reports the Progress of Transactions Under Its Liquidity Program
-
Leading Independent Proxy Advisory Firm Glass Lewis Recommends Ethan Allen Shareholders Vote the WHITE Proxy Card “FOR” All Five of Doug Bergeron’s Director Nominees
-
AL-S Pharma Reports New AP-101 Phase 2 Weight Data and Outlines Phase 3 Clinical Trial in ALS at 2026 NEALS Annual Meeting
-
Tutor Perini Announces Conference Call to Discuss Third Quarter 2026 Results
-
Sable Offshore Corp. Announces Third Quarter 2026 Earnings Release Date and Conference Call
-
Atom Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of Lingdolinurad (ABP-671) for Chronic Kidney Disease with Hyperuricemia
-
OneAdvanced Appoints Emma Brown as Chief Financial Officer
-
DHI Group, Inc. to Report Third Quarter Financial Results on November 4, 2026
-
Berkshire Hathaway Specialty Insurance Promotes Virginie Pelletier to Head of Executive & Professional Liability in France
-
Geogentia Launches Perimeter, Alerts-Only Threat Monitoring for Schools, Organizations, Family Offices and Places of Worship
-
Regional Centres for Education cutting supports to students with exceptionalities to save money: parents, union
-
Joe Amara Executive Search Tapped to Lead Head of Power Origination Search
-
Northern Trust Reappointed by People's Pension
-
Honeywell Technologies Launches Forge Plant Cognition with Dangote, Built with NVIDIA AI and Dell Technologies Capabilities
-
PixVerse and OpenAI Collaborate on “Prompt to Production”, a New Learning Initiative for AI-Powered Creative Workflows
-
Izalontamab Brengitecan (Iza-Bren) Doubles Median Progression-Free Survival in Patients with Previously-Treated EGFR-Mutated Non-Small Cell Lung Cancer Compared to Chemotherapy in the Phase 3 PANKU-Lu
-
PureTech Presents Phase 1b Results for LYT-200 in Relapsed/Refractory (R/R) High-Risk Myelodysplastic Syndromes (HR-MDS) and Acute Myeloid Leukemia (AML) at ESMO 2026
-
Merz Therapeutics Presents New Phase 2 PaiNT Data in Peripheral Neuropathic Pain at IASP 2026
-
CTP launches Serbia's largest industrial and logistics park after securing 10,000 sqm pre-let
-
American Hospital Dubai and HEI Global Health Announce Strategic Partnership to Collaboratively Build an Advanced AI-Powered Revenue Cycle Innovation
-
A Look Ahead at the Highlights of the 9th China International Import Expo
-
Wolters Kluwer selected by IFFCO Tokio General Insurance to support Ind AS 117 and Ind AS 116 compliance with CCH® Tagetik
-
L&T Technology Services and Nokia Forge Engineering Collaboration
-
Alpaca Secures In-Principle Approval from ADGM's FSRA to Expand Brokerage Infrastructure in the UAE
-
Faraday Future Announces YT Jia’s Investor Weekly Report Rescheduled to October 26; FFR to Hold Listing Ceremony and Investor Day on October 26
-
Retail Loss Is Bigger Than External Theft: New IHL Group and Sensormatic Solutions Research Reveals Broader Sources of Loss
-
Ivonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 S
-
Sonesitatug vedotin reduced the risk of death by 42% in 2nd and later-line CLDN18.2-positive advanced gastric/GEJ cancers in CLARITY-Gastric01
-
TAGRISSO® (osimertinib) plus savolitinib reduced the risk of disease progression or death by 45% and the risk of death by 32% in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO
-
Genentech’s Divarasib Demonstrated Best-in-Class Efficacy, Advancing the Standard of Care in Previously Treated KRAS G12C-mutated Lung Cancer
-
Agenus Reports 72% of Patients with Locally Advanced dMMR Colon Cancer Had No Cancer Remaining at Surgery Following Six Weeks of BOT+BAL in Phase 2 NEOASIS Study at ESMO 2026
-
Xencor Presents Phase 1 Dose Selection Data for XmAb819, a Potential First-in-Class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Patients With Advanced Clear Cell Renal Cell Carcinoma and
-
Frontier Medicines Presents Promising Anti-Tumor Activity from Phase 1/2 PROSPER Trial of FMC-376 in a Highly Resistant Patient Population of KRAS G12C-Mutant NSCLC at ESMO 2026
-
Pfizer's 25-Valent Pediatric Pneumococcal Conjugate Vaccine Candidate Shows Robust Phase 2 Data at IDWeek 2026
-
IMFINZI® (durvalumab) plus tarlatamab-dlle reduced the risk of death by 58% in 1st-line extensive-stage small cell lung cancer in the DeLLphi-305 Phase III trial
-
Perioperative IMFINZI® (durvalumab) plus neoadjuvant enfortumab vedotin reduced risk of recurrence by 49% and risk of death by 42% in muscle-invasive bladder cancer
-
Semtech Brings 5G Network Slicing, FIPS 140-3 to IACP 2026
-
ESMO 2026: NUBEQA® (darolutamide) Plus ADT and Radiation Therapy Reduces Risk of Metastasis or Death by 58% in Prostate Cancer Patients at High Risk of Recurrence
-
Incyte and Genmab Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer
-
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026
-
CatalYm Presents Phase 2 Data Showing Visugromab Substantially Enhances the Clinical Benefit of PD-1 Inhibition in Neoadjuvant Bladder Cancer at ESMO 2026
-
Slate Grocery REIT Announces Receipt of Interim Order, and Provides Meeting and Circular Details
-
Genesis Healthcare Announces Effective Date of Chapter 11 Plan Following Consummation of Sale to West State Street
-
US Metro Bancorp Announces Third Quarter 2026 Results
